Next-generation antibody–drug conjugates (ADCs) developed to treat aggressive cancers, with a lead program targeting pancreatic cancer patients. Dual-attack ADCs target both cancer cells and the tumor-supporting stroma to improve drug penetration, overcome resistance, and enhance therapeutic outcomes; proprietary uPAR-targeted ADC in preclinical development.